Brief: Island Pharmaceuticals Says GMP Manufacturing Of Galidesivir Commenced
04/06/2026 24:22
BRIEF-Island Pharmaceuticals Says GMP Manufacturing Of Galidesivir Commenced June 4 (Reuters) - Island Pharmaceuticals Ltd ILA.AX:
GMP MANUFACTURING OF GALIDESIVIR COMMENCED TO SUPPORT PIVOTAL MARBURG STUDY UNDER US FDA'S ANIMAL RULE PATHWAY
EXECUTED AGREEMENT WITH PI HEALTH SCIENCES
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic